Loading...
Market
Will Chimerix secure additional funding beyond $30 million by end of 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Chimerix official press releases or financial statements
Story
Chimerix Submits Dordaviprone NDA for Accelerated Approval to U.S. FDA for Recurrent H3 K27M-Mutant Diffuse Glioma, Secures $30 Million Funding
Dec 30, 2024, 12:02 PM
Chimerix, Inc. has submitted a New Drug Application (NDA) for accelerated approval of its drug, Dordaviprone, to the U.S. Food and Drug Administration (FDA). The application targets patients with recurrent H3 K27M-mutant diffuse glioma, a type of brain cancer. In addition, Chimerix has entered into a credit facility of up to $30 million with Silicon Valley Bank. This funding aims to provide access to additional capital during the upcoming investment cycle and to ensure the availability of Dordaviprone to as many patients as possible, should it receive approval.
View original story
Similar markets
No • 50%
Yes • 50%
Partially utilized • 25%
Not utilized • 25%
Facility withdrawn • 25%
Fully utilized • 25%
No • 50%
Yes • 50%
$200 million to $300 million • 25%
Below $100 million • 25%
Above $300 million • 25%
$100 million to $200 million • 25%
No significant change • 25%
Decrease • 25%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
No • 50%
Yes • 50%
